{"id":22303,"date":"2020-01-17T13:51:35","date_gmt":"2020-01-17T12:51:35","guid":{"rendered":"https:\/\/qlinea.com\/q-linea-intends-to-list-its-shares-on-nasdaq-stockholm\/"},"modified":"2020-01-17T13:51:35","modified_gmt":"2020-01-17T12:51:35","slug":"q-linea-intends-to-list-its-shares-on-nasdaq-stockholm","status":"publish","type":"page","link":"https:\/\/qlinea.com\/us\/q-linea-intends-to-list-its-shares-on-nasdaq-stockholm\/","title":{"rendered":"Q-LINEA INTENDS TO LIST ITS SHARES ON NASDAQ STOCKHOLM"},"content":{"rendered":"<section class=\"header_onlytext headermodule\" style=\"background-color: #fff\" data-text-color=\"#000\">\r\n    <div class=\"wrapper\">\r\n        <div class=\"textWrapper\">\r\n                            <h1 class=\"title\">Q-LINEA INTENDS TO LIST ITS SHARES ON NASDAQ STOCKHOLM<\/h1>\r\n                                <\/div>\r\n    <\/div>\r\n<\/section>\r\n\n\n\r\n<section class=\"content_text contentmodule alignfull\" style=\"background-color: #fff\" data-text-color=\"''\">\r\n    <div class=\"wrapper\">\r\n        <div class=\"textWrapper\"><p>Q-linea AB (publ) (\u201cQ-linea\u201d or the \u201cCompany\u201d), a research, development, and manufacturing company that primarily develops instruments and disposables for rapid infection diagnostics, today announces its intention to launch an initial public offering regarding its shares<a href=\"https:\/\/www.qlinea.com\/en\/q-linea-intends-to-list-its-shares-on-nasdaq-stockholm\/#_ftn1\" name=\"_ftnref1\">[1]<\/a>\u00a0(the \u201cOffering\u201d) and to list its shares on Nasdaq Stockholm (the \u201cListing\u201d).<\/p>\n<ul>\n<li>Nasdaq Stockholm has approved Q-linea\u2019s application for listing subject to customary conditions<\/li>\n<li>A potential Offering will include a new issue of shares in the Company in an amount of a maximum of approximately SEK 632 million (before transaction costs)<\/li>\n<li>A potential Offering will involve that a prospectus is expected to be approved and registered with the Swedish Financial Supervisory Authority (Swe.\u00a0<em>Finansinspektionen<\/em>) and to be published on or around 26 November 2018. The first day of trading is expected to be on or around 7 December 2018<\/li>\n<\/ul>\n<p>The Company has in consultation with the Company\u2019s principal shareholder Nexttobe AB resolved to diversify the ownership of shares in the Company through an issue of new shares. Accordingly, the Company\u2019s board of directors has applied for listing of the Company\u2019s shares on Nasdaq Stockholm. A Listing is expected to support Q-linea\u2019s development of instruments and disposables for rapid infection diagnostics, among other things, through improved access to the capital markets as well as a diversified owner base of new Swedish and international shareholders. Nasdaq Stockholm has approved Q-linea\u2019s application for listing, subject to customary conditions. Four cornerstone investors have in total, subject to certain conditions and for a valuation before the contemplated Offering of the Company\u2019s equity up to SEK 1,037 million, undertaken to acquire shares corresponding to 10.8 % of the outstanding shares in the Company following completion of the Offering and 28.4 % of the Offering.<\/p>\n<h2>Jonas Jarvius, CEO of Q-linea, comments:<\/h2>\n<blockquote><p>\u201c<em>Q-linea is in a very exciting phase, with our main product ASTar approaching clinical studies and the market. The planned IPO will enable us to finalize product development in an efficient manner and initiate clinical studies in relevant markets. We look forward in becoming a listed company and with ASTar be able to help sick patients with infections to return to a normal life<\/em>.\u201d<\/p><\/blockquote>\n<h2>Erika Kjellberg Eriksson, CEO of Nexttobe AB and chairman of the board of Q-linea, comments:<\/h2>\n<blockquote><p>\u201c<em>We invested in Q-linea in 2012 and have through our close cooperation followed the development from idea to close to complete product. We share the Company\u2019s opinion that the first product, ASTar, will save lives of patients with severe sepsis (blood infection), and see the planned listing as an important step in strengthening the Company to reach the planned commercialization<\/em>.\u201d<\/p><\/blockquote>\n<h2>The contemplated Offering in brief<\/h2>\n<p>The contemplated Offering will include a new issue of shares in the Company in an amount of a maximum of approximately SEK 632 million (before transaction costs). The Company intends to use the net proceeds from the new issue to strengthen the Company\u2019s financial position and, provided that the Offering is fully subscribed, the net proceeds are expected to be sufficient to complete the Company\u2019s first product ASTar, obtain regulatory approval for ASTar in the EU and the US as well as future launch of the product in selected geographical markets.<\/p>\n<p>Nexttobe AB will continue to have a significant shareholding in the Company following the Offering. Nexttobe AB have stated that they intend to remain shareholders in the Company.<\/p>\n<p>Four cornerstone investors have, subject to certain conditions, undertaken to in total acquire shares in the transaction corresponding to 10.8 % of the outstanding shares in the Company following completion of the Offering and 28.4 % of the Offering. The four cornerstone investors are Catella Fondf\u00f6rvaltning (3.6 % of the total number of shares in the Company), The Fourth Swedish National Pension Fund (3.0 %), Investment AB \u00d6resund (2.4 %) and L\u00e4nsf\u00f6rs\u00e4kringar Fund Management (1.8 %).<\/p>\n<p>Full terms of the contemplated Offering will be included in a prospectus relating to the Offering, which is expected to be approved by the Swedish Financial Supervisory Authority and published on or around 26 November 2018. The first day of trading is expected to be on or around 7 December 2018.<\/p>\n<h2>Financial information<\/h2>\n<p>Q-linea\u2019s interim report for the period 1 January \u2013 30 September 2018 is available on the Company\u2019s website\u00a0<a href=\"https:\/\/qlinea.com\/\">https:\/\/qlinea.com<\/a>.<\/p>\n<h2>About Q-linea<\/h2>\n<p>Q-linea AB is a diagnostics company focused on developing and delivering solutions for healthcare providers, enabling them to accurately diagnose and treat infectious diseases in the shortest possible time. Our core product, ASTar\u00ae, is a system for quickly and automatically determining the most effective antibiotic for the treatment of infectious diseases. The company was founded in 2008 on technology developed by scientists from the Rudbeck Laboratory at Uppsala University, together with other companies such as Olink Bioscience AB and Uppsala University\u2019s holding company, UUAB.<\/p>\n<h2>About Nexttobe AB<\/h2>\n<p>Nexttobe AB is an investment company with focus on growth equity investments in healthcare, medical devices and specialty pharmaceutical companies but also invests in technology and consumer companies. Nexttobe AB started its investment operations in 2011 and has since its founding invested in more than 30 companies.<\/p>\n<h2>About Catella Fondf\u00f6rvaltning AB<\/h2>\n<p>Catella Fonder, founded in 1997, is an active fund manager focusing on the Nordic markets. Catella manages equity funds, alternative funds, balanced funds and credit funds. Catella Fonder currently has approximately SEK 45 billion under management.<\/p>\n<h2>About the Fourth Swedish National Pension Fund<\/h2>\n<p>Fj\u00e4rde AP-fonden (the Fourth Swedish National Pension Fund) is one of five buffer funds that manage capital on behalf of the Swedish state pension system. Fj\u00e4rde AP-fonden\u2019s mission is to contribute to financial stability for the pensioners of today and the future through managing part of the state pension system\u2019s buffer capital. Fj\u00e4rde AP-fonden\u2019s long-term perspective, responsible ownership and sustainability engagement create opportunities for high returns to a low cost.<\/p>\n<p>In that way, Fj\u00e4rde AP-fonden operates for safer pensions. At the end of 2017 the fund had SEK 357 billion under management, of which SEK 200 billion in stocks.<\/p>\n<h2>About Investment AB \u00d6resund<\/h2>\n<p>Investment AB \u00d6resund is a listed investment company active in asset management. \u00d6resund\u2019s overall goal as an investment company is to run its business in such a way as to generate a healthy long-term return for its shareholders. The investment portfolio includes approximately 25 companies. \u00d6resund has a net asset value of SEK 6.1 billion and a net cash position of SEK 144 million (as of Q3 2018). \u00d6resund\u2019s main owner is the Qviberg family. For more information, see\u00a0<a href=\"http:\/\/www.oresund.se\/\">http:\/\/www.oresund.se<\/a>.<\/p>\n<h2>About L\u00e4nsf\u00f6rs\u00e4kringar Fund Management<\/h2>\n<p>L\u00e4nsf\u00f6rs\u00e4kringar Fund Management is a subsidiary of L\u00e4nsf\u00f6rs\u00e4kringar Bank which is owned by 23 regional insurance companies. The fund volume amounted to SEK 159 billion at the end of 2017 of which SEK 139 billion is managed under its own brand.<\/p>\n<h2>Advisors<\/h2>\n<p>Carnegie Investment Bank AB (publ) is Sole Global Coordinator and Bookrunner. Advokatfirman Lindahl KB is legal advisor to the Company and Nexttobe AB. Baker &amp; McKenzie Advokatbyr\u00e5 KB is legal advisor to Carnegie.<\/p>\n<h2>For further information, please contact:<\/h2>\n<p>Anders Lundin, CFO and IR<br \/>\nTelephone: +46 706 00 15 20<br \/>\nE-mail:\u00a0<a>&#x61;&#x6e;&#x64;&#x65;&#x72;&#115;&#46;&#108;&#117;ndi&#x6e;&#x40;&#x71;&#x6c;&#x69;&#x6e;&#101;&#97;&#46;com<\/a><\/p>\n<p>This information is information that Q-linea AB (publ) is making public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 18.00 CET on 11 November 2018.<\/p>\n<h2>Important information<\/h2>\n<p>This announcement is not an offer to sell or a solicitation of any offer to buy any securities issued by Q-linea AB (publ) (the \u201cCompany\u201d) in any jurisdiction where such offer or sale would be unlawful.<\/p>\n<p>In any EEA Member State, other than Sweden, that has implemented Directive 2003\/71\/EC as amended (together with any applicable implementing measures in any member State, the \u201cProspectus Directive\u201d), this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive.<\/p>\n<p>Any offering of the securities referred to in this announcement will be made by means of a prospectus. This announcement is not a prospectus for the purposes of the Prospectus Directive. Investors should not subscribe for any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus. This document and the information contained herein are not for distribution in or into the United States of America.<\/p>\n<p>This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the \u201cSecurities Act\u201d), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States.<\/p>\n<p>In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, \u201cqualified investors\u201d (as defined in section 86(7) of the Financial Services and Markets Act 2000) and who are (i) persons having professional experience in matters relating to investments who fall within the definition of \u201cinvestment professionals\u201d in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the \u201cOrder\u201d); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as \u201crelevant persons\u201d). Persons who are not relevant persons should not take any action on the basis of this document and should not act or rely on it.<\/p>\n<h2>Forward-looking statements<\/h2>\n<p>Matters discussed in this communication may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as \u201cbelieve\u201d, \u201cexpect\u201d, \u201canticipate\u201d, \u201cintend\u201d, \u201cmay\u201d, \u201cplan\u201d, \u201cestimate\u201d, \u201cwill\u201d, \u201cshould\u201d, \u201ccould\u201d, \u201caim\u201d or \u201cmight\u201d, or, in each case, their negative, or similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialise or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this presentation are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or any obligation to update or revise the statements in this presentation to reflect subsequent events. Undue reliance should not be placed on the forward-looking statements in this document.<\/p>\n<p>The information, opinions and forward-looking statements contained in this communication speak only as at its date and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this communication.<strong>\u00a0<\/strong><\/p>\n<p><a href=\"https:\/\/www.qlinea.com\/en\/q-linea-intends-to-list-its-shares-on-nasdaq-stockholm\/#_ftnref1\" name=\"_ftn1\">[1]<\/a>\u00a0\u201cshares\u201d refer to ordinary shares in the Company<\/p>\n<\/div>\r\n    <\/div>\r\n<\/section>\r\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":68,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"templates\/page-ipo.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-22303","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/pages\/22303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/users\/68"}],"replies":[{"embeddable":true,"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/comments?post=22303"}],"version-history":[{"count":0,"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/pages\/22303\/revisions"}],"wp:attachment":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/media?parent=22303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}